Kala Bio, INC Schedule 13D activist filings

David E. Lazar amends Schedule 13D, reporting beneficial ownership of 719,404 shares, representing 3.9% of Kala Bio, Inc.'s outstanding common stock.

David E. Lazar has acquired a 5.18% beneficial ownership in KALA BIO, Inc. through convertible preferred stock, was appointed CEO and board member, but subsequently resigned as CEO while remaining on the board.

SR One Capital Management entities have reduced their beneficial ownership in KALA BIO, Inc. to 4.6% after converting preferred stock and selling common shares.

Baker Bros. Advisors LP and affiliates have reduced their beneficial ownership in KALA BIO, Inc. to 9.99%, resulting in the loss of their right to nominate directors to the company's Board.

SR One Capital Management and its affiliates reported the sale of 598,940 shares of KALA BIO, Inc. common stock, reducing their beneficial ownership to 5.5%.